Across TCGA pan-cancer cohorts, KRTAP19-6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRTAP19-6 data layer compared with 7 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher KRTAP19-6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP19-6 expression acts as an unfavorable survival marker.

UCS, LUSC, and UCEC are the cancer types where KRTAP19-6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.135	0.687	.009	24	view →
LUSC	DFS	Median	II,III,IV	0.443	0.712	.048	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KRTAP19-6 tumor-vs-normal RNA expression · all KRTAP19-6 data types